For all three PD-L1 inhibitors, the numbers of total and serious irAEs were higher among patients with lung cancer than the other 12 cancers: atezolizumab (49%), avelumab (33%) and durvalumab (87%) (Supplementary Figure S2B). Here, CD274 is linked to cancer.